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Amprenavir (Agenerase, 141-W94, VX-478) is a human immunodeficiency virus type 1 (HIV-1) protease
inhibitor (PRI) recently approved for the treatment of HIV-1 infection in the United States. A major cause of
treatment failure is the development of resistance to PRIs. One potential use for amprenavir is as salvage
therapy for patients for whom treatment that includes one (or more) of the other four currently approved
PRIs—saquinavir, indinavir, ritonavir, and nelfinavir—has failed. We evaluated the cross-resistance to am-
prenavir of viruses that evolved during treatment with the two most commonly prescribed PRIs, nelfinavir and
indinavir. Unexpectedly, a dramatic increase in susceptibility (2.5- to 12.5-fold) was observed with 20 of 312
(6.4%) patient viruses analyzed. The most pronounced increases in susceptibility were strongly associated with
an N88S mutation in protease. All viruses that carried the N88S mutation were hypersensitive to amprenavir.
Site-directed mutagenesis studies confirmed the causal role of N88S in determining amprenavir hypersensi-
tivity. The presence of the N88S mutation and associated amprenavir hypersensitivity may be useful in
predicting an improved clinical response to amprenavir salvage therapy.
Since the discovery of human immunodeficiency virus (HIV)
in the early 1980s, an intense drug discovery effort has resulted
in the approval of 14 antiviral drugs, with many more in de-
velopment (3). The approved drugs inhibit HIV replication by
interfering with the enzymatic activities of either protease
(PR) or reverse transcriptase (RT). The lack of proofreading
functions that is inherent in RT, coupled with error-prone
replication at a high rate, allows HIV to mutate readily. This
high mutation frequency contributes to the ability of HIV to
evade successful long-term therapy, resulting in viral load re-
bound (4).
Multi-drug-resistant HIV variants pose an increasing prob-
lem for the care of infected patients (2, 5, 6, 10). Determina-
tion of the genotypes of such viruses frequently reveals com-
plex patterns of mutations in PR and RT, thus complicating
predictions of sensitivity or resistance to antiviral drugs. Accu-
rate measurements of phenotypic drug susceptibility can be
used to determine patterns of cross-resistance to existing
drugs. This type of analysis is an increasingly important tool for
evaluating investigational or newly approved drugs. The most
recently approved PR inhibitor (PRI), amprenavir, is a prom-
ising candidate for salvage therapies, in part because available
data suggest good activity against viruses resistant to other
PRIs (12, 13, 21).
Utilizing a recently described phenotypic drug-susceptibility
assay (14, 16a), we determined the drug susceptibilities of
viruses present in infected individuals whose combination ther-
apy regimens, including nelfinavir or indinavir, the two most
commonly prescribed PRIs, were failing (viral loads of .500
copies per ml). A measure of relative susceptibility is obtained
by comparing the 50% inhibitory concentration (IC50) for the
patient virus to that for a reference virus, derived from the
NL4-3 infectious HIV type 1 (HIV-1) DNA clone (1). Values
obtained from single measurements that are less than or more
than 2.5-fold those of the reference exceed the normal varia-
tion of the assay and are considered indicative of altered sus-
ceptibility to a drug. Hypersensitivity is defined as a reduction
in the IC50 of $2.5-fold (i.e., a susceptibility value of #0.4)
relative to the NL4-3 reference strain. A significant proportion
of viruses (20 of 312, or 6.4%) from patients that had been
treated with nelfinavir and/or indinavir exhibited hypersensi-
tivity to amprenavir (Table 1).
Table 1 lists drug susceptibility data for 20 patient-derived
viruses, in order of decreasing susceptibility to amprenavir. All
but one of the 20 viruses (patient 17) exhibited decreased
susceptibility to at least one PRI, most frequently nelfinavir.
The PR genotypes of the viruses displaying hypersensitivity to
amprenavir were determined by DNA sequencing using con-
ventional dideoxynucleotide chain terminating sequencing
methods (Perkin-Elmer Biosystems, Foster City, Calif.). De-
duced PR amino acid sequences were compared to that of
NL4-3 (Table 1) and to a list of mutations associated with PRI
resistance (19). Thirteen of the 20 patient virus populations
(65%) and notably all of the viruses displaying the most pro-
nounced increases in susceptibility (#0.2 relative susceptibility,
which corresponds to a $5-fold increase in susceptibility) had
an asparagine (N) to serine (S) substitution in PR at amino
acid position 88. N88S was always observed in combination
with mutations at various other positions, including amino
acids 20, 36, 46, 63, and 77. No viruses from drug-naı¨ve patients
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were found to carry this substitution (2, 10; our unpublished
data). While other changes at amino acid 88, most commonly
N88D, occurred in viruses isolated from patients for whom
treatment with PRIs was failing, these alterations are not cor-
related with a significant increase in susceptibility to amprena-
vir (data not shown). Mutations D30N and V82A, each found
in 3 of the 20 patient-derived viruses listed in Table 1, were less
frequently associated with amprenavir hypersensitivity. How-
ever, the increases in amprenavir susceptibility were less dra-
matic than those with N88S. These substitutions were also
observed in viruses that did not exhibit hypersensitivity to am-
prenavir (data not shown), implying less direct roles for D30N
and V82A in increased amprenavir susceptibility.
A representative PRI susceptibility profile for virus from
patient 1 is shown in Fig. 1. The shift of the amprenavir sus-
ceptibility curve to lower drug concentrations, i.e., to the left of
the reference curve, reflects increased susceptibility. The nelfi-
navir curve is shifted towards higher drug concentrations, i.e.,
to the right, indicating reduced susceptibility. Susceptibilities
to saquinavir, indinavir, and ritonavir did not vary significantly
(less than 2.5-fold) from those of the reference strain.
Based on the available treatment histories of the patients
harboring viruses with hypersensitivity to amprenavir, this phe-
notype appears to be associated with the failure of nelfinavir-
or indinavir-containing treatment regimens. N88S has been
identified previously in viruses isolated after in vitro passage in
the presence of an investigational PRI, SC-55389A (20, 22),
and in viruses isolated from patients treated with nelfinavir
(16). Recently, viruses which emerged early after in vitro se-
lection in the presence of an investigational PRI, BMS 232632,
were found to contain the N88S mutation (4a). Intriguingly,
N88S was found to arise in only two of the three laboratory
strains used, suggesting that different genetic backgrounds
could predispose viruses to alternative resistance pathways of
decreased PRI susceptibility. These data raise the possibility
that new PRIs may select more frequently for the N88S sub-
stitution than do nelfinavir or indinavir.
To delineate the role of individual mutations in PRI suscep-
tibility, site-specific oligonucleotide-directed mutagenesis was
used to generate a series of virus mutants. Mutations were
introduced into the PR coding region of the NL4-3-derived
reference vector using a PCR “megaprimer” method (18). The
presence of the desired mutation(s) and absence of other sub-
stitutions was confirmed by DNA sequencing. Oligonucleotide
RsrII (59-ACTTTCGGACCGTCCATTCCTGGCTTTAATT
TTACTGGTACAG-39) was used to introduce a unique RsrII
restriction site (underlined) approximately 50 nucleotides
downstream of the PR coding region into our drug-sensitive
reference vector. The three point mutations introduced (bold)
do not change the coding sequence of RT. The resulting con-
struct allows an exchange of the PR coding region using a
590-bp ApaI-RsrII fragment, since both restriction sites are
unique. All subsequent mutants were constructed by exchang-
ing ApaI-RsrII fragments. The following oligonucleotides were
used to introduce specific point mutations (bold type): K20T
(59-GGGGGGCAATTAACGGAAGCTCTATTAG-39; cod-
ing strand), M36I (59-GTATTAGAAGAAATAAATTTGCC
AGGAAG-39; coding strand), M46L (59-GATGGAAACCAA
AATTGATAGGGGGAATTG-39; coding strand), L63P (59-G
TATGATCAGATACCCATAGAAATCTGC-39; coding strand),
N88S (59-CTGAGTCAACAGACTTCTTCCAATTATG-39;
noncoding strand). Phenotypic analysis was performed on a
total of 12 mutants (Table 2). Representative susceptibility
curves for nelfinavir, indinavir, and amprenavir for mutant
viruses carrying N88S and L63P/V77I/N88S are shown in Fig.
2. The N88S mutant and all other viable mutants that carried
N88S were hypersensitive to amprenavir, with relative suscep-
tibility values ranging from 0.04 to 0.14. Mutants containing
N88S also displayed reduced susceptibility to nelfinavir (2.39-
to 12.89-fold). Mutant viruses containing L63P or L63P/V77I
TABLE 1. PRI susceptibilities and PR genotypes of 20 patient-derived HIV-1 viruses displaying hypersensitivity to amprenavir
Patient
no.
Relative susceptibilitya PR mutationb
SQV IDV RTV NFV AMP Resistance associated Polymorphism(s)
1 0.73 2.11 1.72 8.92 0.08 K20T, M36I, L63Q, N88S K14R, I15V, E35D, R41K, I62V
2 0.26 6.16 1.50 21.06 0.09 M46L, L63P, N88S I13I/V, E35D, I64V, I72V
3 1.55 3.15 1.22 11.06 0.10 L63P, V77I, N88S I62V
4 1.20 1.49 3.38 15.87 0.15 M36I, L63P, A71A/T, N88S I13V, E35D, I62V
5 1.88 6.31 1.49 29.95 0.15 K20M, M36V, M46I, L63P, N88S I13V, N37A, I62V, I93L
6 1.41 5.47 1.85 16.76 0.16 M46I, L63P, V77I, N88S I93I/L
7 1.28 7.61 3.36 24.67 0.16 M46I, L63P, N88S I13V, K14R, N37D, I93L
8 1.80 7.56 1.95 18.61 0.20 M46I, L63P, V77I, N88S I13V, R41K, I93L
9 1.81 1.15 3.70 5.71 0.23 L10I, K20K/R, M36I, I54V, L63H, L90L/M I13V, I62V, I64V, I72V, N83D
10 2.05 5.58 1.59 15.18 0.24 L10I, M46I, L63P, A71T, V77I, N88S E35D, N37S
11 1.22 4.55 2.55 9.55 0.28 L63P, V77I, N88N/S R41K, I62V, I93I/L
12 0.12 0.77 3.81 1.24 0.29 L10L/F, M36M/L, M46M/I, L63S, V77I, V82A/T I64V, I72T
13 0.38 1.06 8.12 1.65 0.30 K20R, M36I, I54V, V82A R41K, I64V, H69Y
14 8.99 13.59 6.29 63.05 0.30 K20T, L63P, A71V, N88S, L90M I15V, R41K, K45R, R57K, I72M
15 0.54 1.27 0.83 2.59 0.32 K20K/M, L63P, A71A/T, N88N/D/S I13V, I15V, E35D, N37D
16 0.62 1.12 4.36 3.56 0.32 M36I, I54I/V, L63P, A71A/V, V82V/A E35D, I62V, H69Q
17 0.53 0.60 0.57 0.45 0.33 M36M/I, L63Q, V77V/I, N88N/S K14R, I15V, N37N/S, R41K, I62V
18 0.42 1.28 0.63 27.62 0.36 D30N, M36I, L63H, A71V I13V, E35D, N37D, R57K, I62V, I64I/V, I93L
19 0.32 0.69 0.35 2.99 0.37 D30D/N, M36V E35D, N37S, I64V
20 1.16 1.37 1.15 29.13 0.37 D30N, L33I, M36M/I, L63P, N88D T12A/V, I13V, R57K, I93L
a Values represent the fold change in IC50 relative to the reference, representing the mean of the two determinations. Reproducibility studies have demonstrated
the variability of PRI drug susceptibility results to be less than twofold with replicate testing of samples. Mean relative susceptibility values (the IC50 for virus from the
patient divided by the IC50 for the reference) of .2, indicative of reduced susceptibility, or of ,0.5, indicative of increased susceptibility, are highlighted in bold type.
Values are rounded to two decimal places. SQV, saquinavir; IDV, indinavir; RTV, ritonavir; NFV, nelfinavir; AMP, amprenavir.
b Mixed virus populations exhibiting more than one amino acid at given positions are indicated by slashes.
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alone were not hypersensitive to amprenavir, thus confirming
that the N88S mutation is sufficient to determine this pheno-
type. Clearly, M46L, L63P, and V77I each play a role in de-
creased susceptibility to indinavir and nelfinavir when present
in combination with N88S. The L63P/V77I double mutant ex-
hibited a small, 2.49-fold reduction in nelfinavir susceptibility.
The K20T virus displayed increased susceptibility to all five
PRIs, with values ranging from 0.37 to 0.47. No change in
susceptibility to any of the nine approved RT inhibitors was
found (data not shown).
In the absence of drug, the N88S mutant produced signifi-
cantly less luciferase activity than the parental reference virus
FIG. 1. PRI susceptibility profile of virus from patient 1. Susceptibility to PRI drugs was assessed by comparing drug susceptibility curves obtained using the vector
containing PR and RT coding sequences from the patient-derived virus (red lines) with a reference construct containing PR and RT from pNL4-3 (blue lines). The
IC50 is determined from the curve and indicated by vertical lines. The IC50s of saquinavir (SQV), indinavir (IDV), ritonavir (RTV), nelfinavir (NFV), and amprenavir
(AMP) for the reference control were 3.4, 8.3, 20.6, 3.8, and 16.0 nM, respectively.
TABLE 2. Susceptibility to PRIs and relative luciferase activity of HIV-1 mutants
Site-directed PR mutation(s)
Relative susceptibilitya Relative
luciferase
activitybSQV IDV RTV NFV AMP
N88S 0.47 1.56 0.36 2.39 0.04 1.0
L63P, N88S 1.44 2.56 0.77 5.10 0.11 20.7
M46L, L63P, N88S 1.15 2.30 0.85 8.18 0.12 28.0
L63P, V77I, N88S 1.24 3.09 1.39 12.89 0.08 29.3
M46L, L63P, V77I, N88S 1.45 2.97 1.33 12.24 0.14 53.2
K20T 0.37 0.47 0.47 0.43 0.38 10.9
L63P 1.04 1.12 1.27 1.43 1.06 163.9
L63P, V77I 1.24 1.72 1.73 2.49 0.91 75.6
K20T, N88S Not viable ,0.01
K20T, L63P, N88S Not viable ,0.01
K20T, M36I, L63P, N88S Not viable ,0.01
K20T, M46L, L63P, N88S Not viable ,0.01
a Multiple clones that contained the indicated mutations were tested for PRI susceptibility individually (two to five independent clones each), and the mean relative
susceptibilities were determined. See Table 1, footnote a, for PRI abbreviations.
b The mean relative luciferase activity (expressed as a percentage of that of the reference) is defined as relative light units produced by the PR mutant divided by
relative light units produced by the reference virus, in the absence of a drug.
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(;1%). A virus containing both mutations K20T and N88S
could not be analyzed, since it did not produce sufficient lucif-
erase activity. The introduction of additional substitutions at
position 63, positions 36 and 63, or positions 46 and 63 to
K20T/N88S mutants did not restore luciferase activity. To en-
sure that the K20T/N88S mutants did not carry other muta-
tions that might result in inactive constructs, the ApaI-RsrII
restriction fragment covering all of the HIV PR of the K20T/
N88S mutant was exchanged with the equivalent fragment of
the M46L/L63P/V77I/N88S mutant. Luciferase activity was re-
stored, and phenotypic data were consistent with the results
presented in Table 2 (data not shown). Thus, the vector back-
bone used to generate all mutants harboring K20T/N88S is
functional.
Viruses derived from patients 1 and 14 carried both K20T
and N88S substitutions and generated modest amounts of lu-
ciferase activity, although the activity was markedly less than
that of the control (data not shown). One attractive model that
may explain these observations is that these mutants are se-
verely fitness impaired. The luciferase activity measured in the
absence of a drug may be interpreted as an indicator of how
well the recombinant virus pool is able to replicate. Luciferase
activity may serve as a potential measure of replicative fitness
for the following reasons: (i) given equal transfection efficien-
cies with the same test vector DNA pool, relative luciferase
activity is highly reproducible; (ii) relative luciferase activity
values obtained with different viral constructs vary; and (iii)
most, though not all, virus mutants generate lower relative
luciferase activity values than the drug-sensitive reference virus
(our unpublished observations). This is in accordance with the
general idea that the fitness of most drug-resistant HIV vari-
ants is less than that of wild-type HIV. Recombinant viruses
containing N88S have been reported to display delayed growth
kinetics compared to parental wild-type HIV-1 (20, 22), adding
support to this concept. If this is correct, it is likely that addi-
tional mutations, generally referred to as polymorphisms (e.g.,
I15V and R41K), enhance the fitness of patient 1- or 14-
derived virus compared to that of the K20T/N88S site-directed
mutant. Experiments to shed light on these issues and to ex-
plore the suitability of this single-replication-cycle assay to
evaluate viral fitness are currently under way.
It is relevant to determine how the amprenavir concentra-
tions used in the phenotypic assay correlate with plasma drug
levels in patients undergoing therapy. The IC50s and IC95s for
the NL4-3 reference strain and the amprenavir-hypersensitive
patient strains were compared to the estimated trough concen-
trations of amprenavir in plasma (17). Amprenavir has an IC50
of 8 to 16 nM and an IC95 about 10 times higher (100 to 139
nM) for the NL4-3 reference strain. Similar IC50s and IC95s for
wild-type strains have been reported by other investigators
using different assays (9, 13, 15, 21). Values for N88S mutant
viruses ranged from 0.9 to 5.8 nM (IC50) and 7 to 70 nM (IC95).
The concentration of amprenavir in plasma 12 h after a dose of
1,200 mg is approximately 0.65 mg/ml, or 1,300 nM (17). Since
90% of circulating amprenavir is bound to plasma proteins
(11), the effective minimum concentration is 130 nM. Thus, the
range in IC95s for N88S-containing viruses is below the am-
prenavir trough level, whereas that for wild-type viruses some-
FIG. 2. NFV, IDV, and AMP susceptibility curves for two representative mutants with site-directed mutations, N88S and L63P/V77I/N88S. Red lines represent
respective mutant constructs; blue lines represent the reference construct. For drug abbreviations, see the legend for Fig. 1.
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times exceeds it. The decreases in amprenavir IC50 and IC95
observed for viruses carrying the N88S mutation in PR there-
fore appear to be potentially clinically relevant, since such
viruses are less likely to escape the suppressive effects of the
drug than are wild-type viruses with higher IC95 values. When
other variables that negatively affect drug trough levels are
considered, such as alterations in levels of amprenavir binding
proteins (in particular a1-acid glycoprotein) or brief interrup-
tions in drug dosing, the effect of N88S on the viral response to
amprenavir could be even more important.
All of the N88S viruses we analyzed had increased suscep-
tibility to amprenavir. N88S mutant viruses emerge in patients
undergoing nelfinavir and/or indinavir treatment, and this mu-
tation has been linked to decreased susceptibility to both
drugs. This finding is reminiscent of the increase in suscepti-
bility to zidovudine and adefovir caused by the M184V muta-
tion in RT, which confers high-level resistance to 3TC (8; H.
Tian et al., Abstr. 2nd Int. Workshop HIV Drug Resistance
Treatment Strategies, abstr. 30, 1998; M. Miller et al., Abstr.
2nd Int. Workshop HIV Drug Resistance Treatment Strate-
gies, abstr. 34, 1998). However, M184V severely decreases
susceptibility to 3TC, while the N88S substitution, in combina-
tion with other mutations, causes a relatively moderate de-
crease in susceptibility to nelfinavir and indinavir. N88S alone
marginally affects susceptibility to nelfinavir (Table 2). There-
fore, in contrast to M184V, which is readily selected by 3TC
treatment, N88S is less likely to arise as a primary resistance
mutation in response to nelfinavir or indinavir therapy. This
notion is supported by the finding that viruses containing the
N88S substitution alone have not been isolated from patients,
suggesting that N88S may be selected primarily in viruses that
already have other mutations in PR. Alternatively, N88S mu-
tants may arise early but require additional changes in order to
overcome fitness constraints before becoming a predominant
quasispecies.
Based on HIV-1 PR crystal structure data, residue 88 is not
directly involved in substrate or inhibitor binding (7). In wild-
type PR structures, the side chain of N88 forms hydrogen
bonds with the main-chain amide of T74, the main-chain car-
bonyl of T31, and the side-chain Og1 hydroxyl of T31 (Fig. 3).
Mutation of N88 to a serine residue introduces a smaller side
chain. In the published structure of the HIV-1 PR dimer com-
plexed with amprenavir (Protein Data Bank entry 1HPV [7];
www.rcsb.org/pdb/), the D30 side chain of one PR subunit
forms a hydrogen bond with the bound drug, and V32 forms
part of a hydrophobic patch in the drug-binding pocket. The
N88S mutation could lead to the formation of a hydrogen bond
between S88 Og and the main-chain amide of T31, potentially
FIG. 3. Postulated interactions of amprenavir bound to HIV-1 protease. Amprenavir (in gray) is shown interacting with key amino acid residues (in cyan) of HIV-1
PR in the crystal structure of HIV-1 PR complexed with amprenavir (7). Nitrogen and oxygen atoms are colored blue and red, respectively, and OW represents a key
conserved water molecule in the pocket. The molecular surface is calculated using the side-chain atoms of A28, V32, I47, I50, and I84 and Ca of A28. The figure was
drawn using the program SYBYL, version 6.3 (Tripos, Inc.).
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pulling the D30-T31 region towards the site of mutation. This
potential change in the binding pocket could allow the aro-
matic ring of amprenavir to slide further in toward the protein
surface, improving its hydrophobic interactions with amino
acid residues such as A28, V32, I47, I50, and I84 (Fig. 3).
Overall, these changes could improve the amprenavir binding,
which would be consistent with the observed hypersensitivity of
N88S HIV-1 PR to amprenavir. Biochemical characterization
will be required to elucidate the underlying mechanism of drug
susceptibility.
The intricate drug resistance phenotypes displayed by the
N88S (in PR) and M184V (in RT) mutants may be paradigms
for other potentially clinically relevant manifestations. The
complexities of the resistance phenotypes could not have been
accurately predicted by genotypic analysis alone. In light of the
increasing number of patients undergoing highly active anti-
retroviral therapy, these results suggest that phenotypic testing
is helpful in unraveling the potential synergistic interplay of
multiple mutations in determining drug efficacy in vivo. The
detection of drug hypersensitivity suggests a strategy for ther-
apy management that can be tested in the context of a clinical
trial.
We conclude from our studies that amprenavir may have
increased clinical efficacy against N88S viruses. Previous clin-
ical studies found that 3TC-zidovudine combination therapy
was more beneficial than zidovudine monotherapy for patients
harboring M184V viruses (8). By analogy, dual PRI therapy
combining amprenavir with nelfinavir, indinavir, or new drugs
such as BMS-232632 could delay the emergence of viruses
resistant to both PRIs. Some such combinations have already
been reported to be well tolerated (J. Eron et al., Abstr. 5th
Conf. Retroviruses Opportunistic Infect., abstr. 6, 1998).
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